533 Rec'd PCT/PTO 19 JUL 2002

Form PT (REV 5-9		IMERCE PATENT AND TRADEMARK OFFICE	attorney's docket number B45226						
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED / ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371  U.S. APPLICATION NO. (If known, se									
	national application no. /EP00/09367	INTERNATIONAL FILING DATE 22 September 2000	PRIORITY DATE CLAIMED 24 September 1999						
	TITLE OF INVENTION Novel Vaccine Composition								
APPLICANT(S) FOR DO/EO/US  Martin FRIEDE, Veronique HENDERICKX, Philippe HERMAND, Moncef M. SLAOUI, and Stefan G.J. THOELEN									
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:									
1 [] 2. [x									
3. []	This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).								
4. []	A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.								
5. []	<ul> <li>A copy of the International Application as filed (35 U.S.C. 371(c)(2))</li> <li>a. [] is transmitted herewith (required only if not transmitted by the International Bureau).</li> <li>b. [] has been transmitted by the International Bureau.</li> <li>c. [] is not required, as the application was filed in the United States Receiving Office (RO/US).</li> </ul>								
6. []	A translation of the International Application into English (35 U.S.C. 371(c)(2)).								
7. []	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))  a. [] are transmitted herewith (required only if not transmitted by the International Bureau).  b. [] have been transmitted by the International Bureau.  c. [] have not been made; however, the time limit for making such amendments has NOT								
	expired. d. [] have not been made	and will not be made							
8. []		nents to the claims under PCT Article	le 10 (35 II S C 371(a)(3))						
		e inventor(s) (35 U.S.C. 371(c)(4)).	17 (33 G.S. C. 371(c)(3)).						
10. []		to the International Preliminary Ex	amination Report under PCT						
Items 11. to 16. below concern other document(s) or information included:									
		Statement under 37 C.F.R. 1.97 and							
	An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. 3.28 and 3.31 is included.								
	A FIRST preliminary amendment.								
15. [ ]	A SECOND or SUBSEQUENT preliminary amendment.  Please amend the specification by inserting before the first line the sentence:								
	A substitute specification.  A change of power of attorney and/or address letter.								
	A change of power of attorn  An Abstract on a separate sl		•						
	Other items or information:								

us application <b>09/077,263</b>	NO. (if known see 37 CFR 1		INTERNATIONAL APPLICATION NO. PCT/EP00/09367.		ATTORNEYS DOCKET NO. B45226	
	ollowing fees are submit				PTO USE ONLY	
(x )	one month extensio		\$ 110			
() two months extension		on	\$ 400			
() three months extension			\$ 920			
()	four months extensi					
(not beyond statutory time period) \$1,440						
()	fifth month extension	on	\$1,960			
•	ENTER A	\$0.00				
Surcharge of \$130.00 for furnishing the oath or declaration later than o 20 o 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$130.00		
Claims	Number Filed	Number Extra	Rate			
Total claims	- 20 =	0	0 x \$18.00	\$0.00		
Independent claims	- 3 =	0	0 x \$84.00	\$0.00		
Multiple depend	ent claims (if applicable	e)	+ \$280.00	\$0.00		
		\$130.00				
•	2 for filing by small entialso be filed. (Note 37 C	\$				
		\$130.00				
-	f \$130.00 for furnishing s from the earliest claim	\$				
,		\$130.00				
(AYPAGH 00000091	192570 10088748	Amount to be refunded	·			
130.00 CM		charged	\$			

07/24/2002 ( 01 FC:154

- a. \(\sigma\) A check in the amount of \(\sigma\) to cover the above fees is enclosed.
- b. E Please charge my Deposit Account No. <u>19-2570</u> in the amount of <u>\$130.00</u> to cover the above fees. A duplicate copy of this sheet is enclosed.
- c. Enterown The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-2570. A duplicate copy of this sheet is enclosed.
- d. E General authorization to charge any and all fees under 37 CFR 1.16 or 1.17, including petitions for extension of time relating to this application. (37 CFR 1.136 (a)(3)).

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

**GLAXOSMITHKLINE** 

Corporate Intellectual Property - UW2220

P.O. Box 1539

King of Prussia, PA 19406-0939

Phone (610) 270-5968

Facsimile (610) 270-5090

SIGNATURE

William R. Majarian

NAME

41,173

REGISTRATION NO.

n:\will\apps\b45226\2ndsub.doc

## **PATENT** ATTORNEY'S DOCKET NUMBER B45226

## TRANSMITTAL LETTER TO THE U.S. DESIGNATED/ELECTED OFFICE (DO/EO/US) – CONCERNING A FILING UNDER 35 U.S.C 371

INTERNATIONAL APP. NO. INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED

PCT/EP00/09367

22 September 2000

24 September 1999

TITLE OF INVENTION

**Novel Vaccine Composition** 

APPLICANT(S) FOR DO/US

Martin FRIEDE, Veronique HENDERICKX, Philippe HERMAND, Moncef M. SLAOUI, and Stefan G.J. THOELEN

**Box PCT** 

Assistant Commissioner for Patents

Washington, D.C. 20231 ATTENTION: DO/US

### **CERTIFICATION UNDER 37 CFR 1.10**

I hereby certify that this Transmittal Letter, Form PTO 1390 and the papers indicated as being transmitted therewith, and Post Card are being deposited with the United States Postal Service on this date July 19, 2002 in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number EV104999112US addressed to the: Assistant Commissioner for Patents,

Washington, D.C. 20231.

(Typed or printed name of person mailing paper)

20462

PATENT TRADEMARK OFFICE



#### UNITED STATES PATENT AND TRADEMARK OFFICE



Commissioner for Patents, Box PCT Umtext States Patent and Trademark Office Washington, D.C. 20231

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	TTA	ATTY. DOCKET NO.	
10/088,748	Martin Friede		345226	
		INTERNATIONAL AP	PLICATION NO.	
		PCT/EP00	/09367	
20462		I.A. FILING DATE	PRIORITY DATE	
SMITHKLINE BEECHAM CORPORATION		09/22/2000	09/24/1999	

20462 SMITHKLINE BEECHAM CORPORATION CORPORATE INTELLECTUAL PROPERTY-US, UW2220 P. O. BOX 1539 KING OF PRUSSIA, PA 19406-0939

CONFIRMATION NO. 8803 371 FORMALITIES LETTER

\*OC000000008166206

Date Mailed: 05/22/2002

# NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fees
- Priority Document
- Copy of IPE Report
- o Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- Information Disclosure Statements
- Preliminary Amendments

Request for Immediate Examination

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date.
- \$130 Surcharge for providing the oath or declaration later than the appropriate 30 months months from the priority date (37 CFR 1.492(e)) is required.

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTH FROM THE DATE OF THIS NOTICE OR BY 22 or 32 MONTHS (where 37 CFR 1.495 applies) FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).